Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
13 Jun 24
8-K
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
14 May 24
8-K
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
8 May 24
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Pacira BioSciences Reports First Quarter 2024 Financial Results
7 May 24
ARS
2023 FY
Annual report to shareholders
22 Apr 24
DEFA14A
Additional proxy soliciting materials
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
S-8
Registration of securities for employees
29 Feb 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
29 Feb 24
8-K
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
4 Jan 24
8-K
Pacira Appoints Frank D. Lee as Chief Executive Officer
21 Dec 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Pacira BioSciences Reports Third Quarter 2023 Financial Results
2 Nov 23
UPLOAD
Letter from SEC
24 Oct 23
8-K
Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors
10 Oct 23
CORRESP
Correspondence with SEC
6 Oct 23
8-K
Pacira BioSciences Announces Leadership Succession Plan
26 Sep 23
UPLOAD
Letter from SEC
22 Sep 23
8-K
Other Events
11 Sep 23
S-8
Registration of securities for employees
2 Aug 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
8-K
Pacira BioSciences Reports Second Quarter 2023 Financial Results
2 Aug 23
8-K
Departure of Directors or Certain Officers
20 Jun 23
10-Q
2023 Q1
Quarterly report
3 May 23
8-K
Pacira BioSciences Reports First Quarter 2023 Financial Results
3 May 23
ARS
2022 FY
Annual report to shareholders
21 Apr 23
DEFA14A
Additional proxy soliciting materials
21 Apr 23
DEF 14A
Definitive proxy
21 Apr 23
8-K
Pacira BioSciences Announces Repayment and Termination of Term Loan B Facility Using
3 Apr 23
8-K
Pacira BioSciences Announces Departure of Yvonne Greenstreet from Board of Directors
22 Mar 23
10-K
2022 FY
Annual report
28 Feb 23
8-K
Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results
28 Feb 23
8-K
Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million
5 Jan 23
8-K
Pacira BioSciences Reports Preliminary Net Product Sales of $57.5 Million for November 2022
13 Dec 22
8-K
Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2022
14 Nov 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Pacira BioSciences Reports Third Quarter 2022 Financial Results
3 Nov 22
8-K
Pacira BioSciences Reports Preliminary Third Quarter 2022 Revenue of $167.5 Million
13 Oct 22
Latest ownership filings
4
LAUREN RIKER
13 Jun 24
4
JONATHAN SLONIN
13 Jun 24
4
CHRISTOPHER CHRISTIE
13 Jun 24
4
MARCELO BIGAL
13 Jun 24
4
Charles A. Reinhart III
13 Jun 24
4
MICHAEL J. YANG
13 Jun 24
4
Abraham Ceesay
13 Jun 24
4
DARYL GAUGLER
13 Jun 24
4
Mark Froimson
13 Jun 24
4
Alethia Young
13 Jun 24
4
PAUL J HASTINGS
13 Jun 24
4
KRISTEN WILLIAMS
13 Jun 24
4
Laura Brege
13 Jun 24
4
Mark A. Kronenfeld
13 Jun 24
144
Notice of proposed sale of securities
13 Jun 24
144
Notice of proposed sale of securities
13 Jun 24
144
Notice of proposed sale of securities
13 Jun 24
144
Notice of proposed sale of securities
12 Jun 24
144
Notice of proposed sale of securities
11 Jun 24
4
LAUREN RIKER
5 Jun 24
4
Charles A. Reinhart III
5 Jun 24
4
KRISTEN WILLIAMS
5 Jun 24
4
DARYL GAUGLER
5 Jun 24
4
JONATHAN SLONIN
5 Jun 24
4
GARY W PACE
8 Mar 24
144
Notice of proposed sale of securities
6 Mar 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
KRISTEN WILLIAMS
7 Feb 24
4
DARYL GAUGLER
7 Feb 24
SC 13G/A
BlackRock Inc.
19 Jan 24
4
LAUREN RIKER
4 Jan 24
4
JONATHAN SLONIN
4 Jan 24
4
Frank D. Lee
4 Jan 24
3
Frank D. Lee
4 Jan 24
3
JONATHAN SLONIN
7 Dec 23
144
Notice of proposed sale of securities
13 Nov 23
4
Alethia Young
11 Oct 23
4
MICHAEL J. YANG
11 Oct 23
4
MARCELO BIGAL
11 Oct 23
4
Abraham Ceesay
11 Oct 23